
zzso of zzso to zzso carriers may alter drug disposition and improve zzso zzso We have performed a clinical phase I trial of zzso coupled to zzso zzso zzso The drug was administered as single dose zzso every zzso zzso Thirteen patients have received a total of 24 courses zzso 2; range zzso At the starting dose of 40 zzso zzso equivalent zzso WHO grade IV zzso was noted in zzso zzso WHO grade IV zzso and WHO grade III zzso were noted in a patient with zzso heart zzso Five patients were treated with zzso zzso zzso zzso toxicity at this dose level was WHO grade III zzso and local zzso zzso grade zzso in zzso patients, zzso of alkaline zzso zzso grade zzso and WHO grade III vomiting in another zzso zzso five patients received 20 zzso zzso zzso was noted in zzso patients (1 zzso WHO grade IV, 1 zzso WHO grade zzso zzso was noted in zzso patients (1 zzso WHO grade IV, 2 zzso WHO grade zzso At zzso zzso zzso a patient diagnosed with a zzso zzso zzso had stable disease for 4 zzso zzso analyses of total and free zzso were performed in plasma and zzso The maximum peak plasma concentration zzso for total zzso was zzso zzso at 40 zzso zzso The area under the plasma concentration time curve zzso ranged from zzso zzso with zzso elimination half lives zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso zzso AT 250 zzso 

